CD19 and acute lymphoblastic leukemia: found that lymphodepletion with cyclophosphamide and fludarabine did not significantly impact the MRD-negative rate or the incidence of severe CRS in unclassified ALL, suggesting that lymphodepletion may not enhance anti-CD19 CAR-T therapy outcomes in these cases (12).